公式タイトルと情報はIP Exchange PlusとPremiumのユーザーのみが利用可能です。
特許 権利維持 Because of the Akt[1] functions above, Akt inhibitors may treat cancers such as neuroblastoma. Some Akt inhibitors have undergone clinical trials. In 2007 VQD-002 had a phase I trial.[26] In 2010 Perifosine reached phase II.[27] but it failed phase III in 2012. Miltefosine is approved for leishmaniasis and under investigation for other indications including HIV.
追加情報の詳細を見るにはIP Exchange PlusまたはIP Exchange Premiumアカウントにアップグレードする必要があります
